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ABSTRACT
Background and Objectives: Little evidence is available on the optimal antithrombotic therapy following percutaneous cor-
onary intervention (PCI) in patients with atrial fibrillation (AF). We investigated the outcomes of antithrombotic treatment 
strategies in AF patients who underwent PCI. Subjects and Methods: Three hundred sixty-two patients (68.0% men, mean 
age: 68.3±7.8 years) with AF and who had undergone PCI with stent implantation between 2005 and 2007 were enrolled. 
The clinical, demographic and procedural characteristics were reviewed and the stroke risk factors as well as antithrombotic 
regimens were analyzed. Results: The accompanying comorbidities were as follows: hypertension (59.4%), diabetes (37.3%) 
and congestive heart failure (16.6%). The average number of stroke risk factors was 1.6. At the time of discharge after PCI, 
warfarin was prescribed for 84 patients (23.2%). Cilostazol was used in addition to dual antiplatelet therapy in 35% of the pa-
tients who did not receive warfarin. The mean follow-up period was 615±385 days. The incidences of major adverse cardiac 
events (MACE), stroke and major bleeding were 11.3%, 3.6% and 4.1%, respectively. By Kaplan-Meier survival analysis, war-
farin treatment was not associated with a lower risk of MACE (p=0.886), but it was associated with an increased risk of major 
bleeding (p=0.002). Conclusion: Oral anticoagulation therapy after PCI may increase hemorrhagic events in Korean AF 
patients. (Korean Circ J 2011;41:578-582)
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhy-
thmia and it is associated with an increased risk of thrombo-
embolic events. Oral anticoagulation with warfarin should 
be considered for the patients with AF and who have multiple 
risk factors to prevent ischemic stroke.
1) Several meta-analy-
ses have shown that warfarin treatment in patients with non-
valvular AF is associated with a lower risk of ischemic stroke 
and cardiovascular events, but it is also associated with an el-
evated risk of major hemorrhage.
2)3)
Antithrombotic strategies become problematic when AF pa-
tients who require warfarin subsequently have to undergo 
percutaneous coronary intervention (PCI) with stent impl-
antation. The 2006 American College of Cardiology/Ameri-
can Heart Association/European Society of Cardiology guide-
lines on AF management
1) suggest that the maintenance re-
gimen should consist of a combination of clopidogrel plus 
warfarin for 9 to 12 months, followed by warfarin monoth-
erapy in the absence of a coronary event. However, others have 
suggested different management guidelines
4) and none of the 
issued guidelines have been based on prospective randomized 
trials.
The aim of this study was to investigate whether the use of 
oral anticoagulants is associated with better clinical outcomes Sung-Won Jang, et al.   579
in Korean AF patients who undergo PCI with stenting.
Subjects and Methods
We performed this retrospective analysis using the infor-
mation obtained from the registry databases at five cardio-
vascular centers. The study subjects were AF patients who un-
derwent PCI with stent implantation between January 2005 
and December 2007. All patients with a previous diagnosis 
of paroxysmal, persistent or permanent AF were enrolled, and 
those who developed new onset AF at the time of admission 
for PCI were also included.
We reviewed the procedural, patient, clinical and demo-
graphic characteristics. The stroke risk factors and the anti-
thrombotic therapy administered on admission and at disch-
arge were recorded. The stroke risks were assessed by using the 
CHADS2 scoring system (1 point each is assigned for cardiac 
failure, hypertension, an age over 75 years and diabetes while 
2 points are assigned for a history of stroke or transient isch-
emic attack).
5) The left ventricular ejection fraction was re-
corded, as was measured by transthoracic echocardiography 
using the modified Simpson’s method.
The individual patient management decisions were made 
by the attending cardiologists. All coronary procedures were 
decided on by the attending interventional cardiologists, as 
were the strategies for oral anticoagulation and antiplatelet 
drugs at discharge, which was based on the type of AF, the st-
roke risk factors, the revascularization procedures and the 
types of implanted stents.
Patients were followed up at 1 to 2 month intervals in an 
outpatient clinic setting. The patients who were administered 
warfarin were monitored for prothrombin time. The warfarin 
doses were adjusted to maintain an international normaliz-
ed ratio (INR) target range of 2.0 to 3.0. We collected total INR 
data for each patient and determined whether they were 
above, below or within the therapeutic range (2.0-3.0). The 
percentage of each range was averaged in all patients. Infor-
mation was obtained by reviewing the medical records and 
by conducting telephone interviews with the patients or the 
patients’ families. Death was determined from the family mem-
bers or from the hospital discharge summaries.
The study protocol was approved by the institutional ethics 
committee of each center, and written informed consent for 
the procedure was obtained from all patients.
End point definitions
The primary end point was defined as the occurrence of 
major adverse cardiac events (MACEs), which included dea-
th, myocardial infarction and target vessel revascularization. 
The secondary safety end points were defined as major ad-
verse events (MAEs), which included any MACE, a bleeding 
episode or stroke during follow-up. Myocardial infarction was 
diagnosed if a typical rise and fall in cardiac biochemical mar-
kers {troponin or creatine kinase-MB (CK-MB)} was accom-
panied by at least one of the following: symptoms of ische-
mia, electrocardiography (ECG) changes indicative of new 
ischemia (new ST-T changes or new left bundle branch blo-
ck), the development of pathological ECG Q waves, imaging 
evidence of a new loss of viable myocardium or a new regio-
nal wall motion abnormality. Stent thrombosis was defined 
as symptoms suggestive of an acute coronary syndrome and 
angiographic confirmation of thrombosis.
Major bleeding was defined as a decrease in hemoglobin 
of 2 g/dL or more over a 24-hour period, the need for a tr-
ansfusion of two or more units of packed red blood cells, ble-
eding leading to death and bleeding at the following critical 
sites: intracranial, intraspinal, intraocular, pericardial, intra-
articular, retroperitoneal or intramuscular bleeding with com-
partment syndrome. Minor bleeding was defined as acute cli-
nically overt bleeding that did not meet the criteria for major 
bleeding, such as nasal or gastrointestinal bleeding, hematu-
ria, ecchymosis or hemoptysis.
Statistical analysis
Statistical analyses were performed using Statistical Pack-
age for the Social Sciences (SPSS) version 12.0 (SPSS Inc., Chi-
cago, IL, USA). The continuous variables with normal distri-
butions were expressed as means±SDs and these were com-
pared using an unpaired Student’s t-test and nonparametric 
variables were compared using a Mann-Whitney U test. Ca-
tegorical variables were compared with a Fisher’s exact test or 
the χ2 test, as appropriate. All comparisons were two-sided, 
and p<0.05 were regarded as being statistically significant.
Event-free survivals were estimated using the Kaplan-Me-
ier method and they were compared using the log-rank test. 
Multivariate analysis was performed using the Cox propor-
tional hazard model (the ‘Enter method’). Variables that sh-
owed a p<0.15 on the univariate analysis or that could influ-
ence the clinical outcomes regardless of the univariate p were 
entered in the multivariate analysis. Variables included in the 
multivariate analysis were age, type of AF, hypertension, dia-
betes, the previous use of clopidogrel and/or warfarin, and the 
total number of stents.
Results
Baseline characteristics
We reviewed the records of 362 patients (68.0% men, mean 
age: 68.3±7.8 years). The characteristics of the study popula-
tion in relation to the use of oral anticoagulants at discharge 
are shown in Table 1. The anticoagulation group was slightly 
younger than the non-anticoagulation group. Of the 362 pa-
tients, 150 (41.4%) had paroxysmal AF. In total, 45.5% of pa-
tients had a CHADS2 score of ≥2. The indications for PCI 580   Antithrombotics in AF Patient After PCI
were chronic stable angina (43%) and acute coronary syn-
drome (57%). Drug-eluting stents were used in most cases 
and a Cypher stent (Cordis Corporation, Miami, FL, USA) 
was used more frequently than a Taxus stent (Boston Scienti-
fic, Natick, MA, USA). Two or more stents were implanted 
in 43.8% of the patients.
The antithrombotic drug regiment at discharge
The antithrombotic regimens used at discharge are sum-
marized in Table 2. Anticoagulation with warfarin was used 
in 23% of the patients. Cilostazol was used in 35% of the pa-
tients who did not receive warfarin. None of the patients re-
ceived monotherapy at discharge. In the anticoagulation gr-
oup, 17% of the patients discontinued warfarin within 1 year 
due to side effects or poor compliance. Aspirin, clopidogrel 
and cilostazol were usually administered at least 1 year after 
the procedure regardless of the type of stent used. Patients on 
oral anticoagulation therapy had INR values in the therapeu-
Table 1. Baseline characteristics classified by anticoagulation therapy at discharge
Whole cohort (n=362) Not anticoagulated (n=278) Anticoagulated (n=84) p
Age (years) 68.3±7.80 69.0±7.90 66.0±7.20 0.003
Paroxysmal AF (%) 41.4 43.2 35.7 0.224
Male (%) 68.0 68.0 67.9 0.982
Hypertension (%) 59.4 59.0 60.7 0.778
Diabetes mellitus (%) 37.3 35.6 42.9 0.229
Stroke (%) 10.8 09.7 14.3 0.236
Heart failure (%) 16.6 17.3 14.3 0.520
CHADS2 risk score 1.6±1.2 1.6±1.2 1.6±1.4 0.997
Dialysis (%) 02.5 02.9 0 0.116
LVEF (%) 53.2±10.9 53.5±11.3 52.5±9.70 0.505
Treatment on admission (%)
    Aspirin 39.8 39.9 39.3 0.916
    Clopidogrel 06.6 05.4 10.7 0.086
    Warfarin 07.5 04.3 17.9 <0.001
Indication for PCI (%) 0.237
    Stable angina 42.8 40.6 500.
    Unstable angina 20.7 20.5 21.4
    NSTEMI 17.4 19.4 17.4
    STEMI 19.1 19.4 19.0
Stents (%) 
    Cypher 69.3 67.6 75.0 0.199
    Taxus 38.1 37.8 39.3 0.802
    Bare metal stent 09.1 08.6 10.7 0.561
Total stent number 1.6±0.8 1.7±0.9 1.5±0.6 0.138
Total stent length (mm) 37.2±20.9 37.1±21.8 37.4±17.5 0.907
Average stent diameter (mm) 3.10±0.40 3.13±0.38 3.15±0.36 0.782
AF: atrial fibrillation, LVEF: left ventricular ejection fraction, PCI: perdutaneous coronary intervention, NSTEMI: non-ST elevation myocar-
dial infarction, STEMI: ST elevation myocardial infarction
Table 2. Antithrombotic regimens adopted in AF patients at discharge
Antithrombotic regimen, n (%) Whole cohort (n=362) Chronic AF (n=212) Paroxysmal AF (n=150)
Aspirin+clopidogrel 182 (50.3) 102 (48.1) 80 (53.3)
Aspirin+clopidogrel+warfarin 073 (20.2) 046 (21.7) 27 (18.0)
Aspirin+clopidogrel+cilostazol 093 (25.7) 054 (25.5) 39 (26.0)
Aspirin+clopidogrel+cilostazol+warfarin 08 (2.2) 05 (2.4) 3 (2.0)
Aspirin+cilostazol 03 (0.8) 02 (0.9) 1 (0.7)
Clopidogrel+warfarin 03 (0.8) 03 (1.4) 0 (0)0.
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tic range (2.0-3.0) 52% of the time; 27% of the time they were 
below and 21% of the time, they were above 3.0.
Clinical outcomes
Clinical follow-up records were analyzed for the patients 
(average length of follow-up: 615±385 days). Clinical events 
during follow-up and according to the use of oral anticoagu-
lants are summarized in Table 3. The use of warfarin did not 
affect the MACEs or MAEs by Kaplan-Meier survival analy-
sis (Log-Rank test) (Fig. 1). On the Cox regression analysis, 
diabetes was an independent predictor of both MACEs {haz-
ard ratio (HR)=1.775; 95% confidence interval (CI): 1.142 to 
2.760} and MAEs (HR=4.543; 95% CI: 2.260 to 9.131), but 
anticoagulation with warfarin was not (HR=0.943 with 95% 
CI, 0.556 to 1.593 and HR=0.755 with 95% CI, 0.346 to 1.649, 
respectively). In addition, multivariate analysis for major ble-
eding was performed. Independent predictors for major ble-
eding were total stent number (HR=2.020 with CI, 1.045 to 
3.943) and warfarin use (HR=7.564 with CI, 2.051 to 27.895).
Discussion
The aim of this study was to investigate whether oral anti-
coagulation adds benefit to the antiplatelet therapy in Asian 
AF patients who underwent PCI with stent implantation. In 
this study, the occurrence of clinical events was found to be 
independent of warfarin use at discharge. Ruiz-Nodar et al.
6) 
reported that warfarin could reduce MACEs primarily by re-
ducing target vessel failure and death in a study that focused 
on a similar group of patients. In that study, the commonly 
used regimen for those who do not receive warfarin was a 
combination of aspirin and clopidogrel. None of the patients 
received cilostazol as an antithrombotic agent. In our study, 
cilostazol was used in 35% of the non-anticoagulation group. 
Recent studies have shown that adding cilostazol to aspirin 
and clopidogrel can reduce the incidence of target lesion re-
vascularization in patients who have undergone PCI with 
drug-eluting stents.
7) Women, diabetics and those having mul-
tivessel disease or a long stent length are more likely to bene-
Table 3. Clinical events during follow-up
Event, n (%) Not anticoagulated (n=278) Anticoagulated (n=84) p
Death 23 (8.3) 03 (3.6) 0.144
AMI 04 (1.4) 03 (3.6) 0.206
TLR 12 (4.3) 01 (1.2) 0.132
Stent thrombosis 04 (1.4) 03 (3.6) 0.206
Major bleeding 06 (2.2) 09 (10.7) 0.002
Minor bleeding 03 (1.1) 02 (2.4) 0.329
Stroke 12 (4.3) 01 (1.2) 0.314
MACE 43 (15.5) 10 (11.9) 0.849
MAE 64 (23.0) 22 (26.2) 0.550
AMI: acute myocardial infarction, TLR: target vessel revascularization, MACE: major adverse cardiac event, MAE: major adverse event
Fig. 1. Kaplan-Meier survival curves in relation to the use of anticoagulants drugs at discharge. A: major adverse cardiovascular events, 
p=0.886. B: major adverse events, p=0.637. Solid and dotted line indicates no anticoagulation use and anticoagulation use at discharge, 
respectively.
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fit from triple antiplatelet therapy.
8)9) In our study’s non-anti-
coagulation group, the mean total stent length was 37.1 mm 
and 35.6% of the patients had diabetes; these patients might 
have derived some benefit from a triple antiplatelet regimen. 
The incidence of ischemic stroke in the non-anticoagula-
tion group was not significantly different from that in the 
anticoagulation group. ACTIVE-W study showed that war-
farin is superior to clopidogrel plus aspirin for the preven-
tion of vascular events in patients with AF.
10) Dose adjustment 
and close monitoring of the prothrombin time are prerequi-
sites for successful anticoagulation therapy. In a subanalysis 
of the ACTIVE-W study, inadequate control of the INR did 
not provide benefit of oral anticoagulation over dual anti-
platelet therapy.
11) In our study, patients in the oral anticoag-
ulation group had an INR value within the therapeutic range 
52% of the time, which is low compared with 64% in the AC-
TIVE-W study. This might compromise the benefit of anti-
coagulation therapy. 
The incidence of major bleeding in the oral anticoagula-
tion group was significantly higher than that in the non-an-
ticoagulation group. A combination of antiplatelet and anti-
coagulation drugs usually carries a greater risk of bleeding 
than that of each drug alone.
12) In addition, Asians are more 
vulnerable to major bleeding and intracranial hemorrhage 
than are non-Asians in the context of warfarin use.
13)14) The war-
farin dose requirements are affected by polymorphisms in 
P450 cytochrome CYP2C9,
15) and by variants in the gene ex-
pressing vitamin K epoxide reductase complex 1 (VKORC1), 
which is the target enzyme of warfarin.
16) Therefore, Asians 
may require a lower warfarin dosage and this is probably due 
to the differences in the allelic frequencies of the CYP2C9 
and VKORC1 variants.
17) 
This study has several limitations. First, given the low rate 
of bleeding events, the power of the study to detect significant 
differences in MACEs was limited. Second, the follow-up 
periods varied widely because of the retrospective design of 
the study. Third, the interval of INR measurement for pa-
tients on the oral anticoagulation group was also variable in 
each patient.
In conclusion, oral anticoagulation therapy after PCI may 
increase hemorrhagic events in Korean AF patients. Warfa-
rin should be administered more carefully in these patients.
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